NR4A1 and breast cancer: However, there were no significant differences in progesterone receptor (PR) positivity [67% (76/114) vs. 72% (100/138)], human epidermal growth factor receptor (Her-2/neu) positivity [18% (20/114) vs. 10% (14/138)] or combined hormone receptor status (ER and PR considered together) or BC subtypes (i.e., Luminal A and B, basal-like and unclassified) [22].